Solanezumab (LY2062430)

solanezumab · Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Solanezumab (LY2062430), covering 2018-07-24 to 2018-07-24. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease [Phase 3]